Study Description: The purpose of this research study is to evaluate an investigational drug (DFMO) for neuroblastoma that is in remission. This study will look at the ability of the study drug to keep the tumor in remission and will also look at the safety and tolerability of DFMO. DFMO was shown to be effective in inhibiting tumor growth in adult colon cancer and has been tested in multiple adult clinical trials and four pediatric trials. Laboratory testing in neuroblastoma suggests that this drug may be effective in treating this disease.
Principal Investigator: Colleen McDonough
Eligibility Criteria: Inclusion*: - Age: less than or equal to 30.99 years of age - Diagnosis: histologic verification at either the time of original diagnosis or a previous relapse of high risk neuroblastoma. - Disease Status: Neuroblastoma that is in remission - Less than 60 days from last dose of previous therapy. - A negative pregnancy test is required for female subjects of child bearing potential (onset of menses or greater than or equal to 13 years of age). - ANC > 500/ul and platelet count >50,000/ul - Organ Function Requirements: Total absolute phagocyte count greater than or equal to 1000/uL AST and ALT Serum creatinine based on age/gender table Exclusion*: - Lansky < 60% - BSA (m2) of - Currently receiving other Investigational drug therapy - Infection not under control *Additional criteria may apply
Compensation: No, subjects will not be compensated.
If you don't see specific studies that interest you, please submit your contact information for future studies.